Peter T. Cangany, Jr. Buys 75,000 Shares of Beneficient (NASDAQ:BENF) Stock

Beneficient (NASDAQ:BENFGet Free Report) Director Peter T. Cangany, Jr. acquired 75,000 shares of the stock in a transaction on Tuesday, November 19th. The stock was bought at an average price of $0.93 per share, with a total value of $69,750.00. Following the transaction, the director now directly owns 300,000 shares in the company, valued at approximately $279,000. This represents a 33.33 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Beneficient Price Performance

Shares of Beneficient stock opened at $0.82 on Thursday. The firm has a 50 day simple moving average of $1.27 and a 200 day simple moving average of $2.43. Beneficient has a fifty-two week low of $0.72 and a fifty-two week high of $51.14.

Institutional Investors Weigh In On Beneficient

A hedge fund recently raised its stake in Beneficient stock. Stifel Financial Corp lifted its stake in Beneficient (NASDAQ:BENFFree Report) by 138.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 24,300 shares of the company’s stock after purchasing an additional 14,100 shares during the period. Stifel Financial Corp owned 0.57% of Beneficient worth $30,000 at the end of the most recent quarter. 90.57% of the stock is currently owned by hedge funds and other institutional investors.

Beneficient Company Profile

(Get Free Report)

Beneficient, a technology-enabled financial services company, provides liquidity solutions and related trustee, custody and trust administrative services to participants in the alternative asset industry in the United States. It operates through Ben Liquidity, Ben Custody, and Customer ExAlt Trusts segments.

See Also

Insider Buying and Selling by Quarter for Beneficient (NASDAQ:BENF)

Receive News & Ratings for Beneficient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beneficient and related companies with MarketBeat.com's FREE daily email newsletter.